Search
Hengrui Medicine: Recizumab and Adebelimab Injections Proposed for Breakthrough Therapy Status
6 day ago /
Read about 0 minute
Author：小编
Hengrui Medicine's subsidiaries, Suzhou Shengdia Biopharmaceutical and Shanghai Shengdi Pharmaceutical, have successfully included their Recizumab Injection and Adebelimab Injection in the National Medical Products Administration's proposed list of breakthrough therapies. Recizumab is specifically designed for adult patients diagnosed with non-small cell lung cancer (NSCLC) that harbors HER2 activating mutations. On the other hand, Adebelimab is intended for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The respective cumulative R&D investments for these two innovative products amount to approximately 1,259.15 million yuan and 901.30 million yuan.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
